147610-85-3

Basic information

• Product Name: 6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid
• Synonyms: 6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid;6-Cbz-6-azaspiro[2.5]octane-1-carboxylic acid;6-Aza-spiro[2.5]octane-1,6-dicarboxylic acid 6-benzyl ester
• CAS NO: 147610-85-3
• Molecular Formula: C₁₆H₁₉NO₄
• Molecular Weight: 289.32636
• Mol File: 147610-85-3.mol

Chemical Properties

• Boiling Point: 479.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• PKA: 4.71±0.20(Predicted)
• CAS DataBase Reference: 6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(147610-85-3)
• EPA Substance Registry System: 6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid(147610-85-3)

Safety Data

• Hazardous Substances Data: 147610-85-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is used as a building block for the synthesis of new drugs or treatment options, leveraging its unique structure and properties to contribute to the development of innovative pharmaceuticals.
Used in Medicinal Chemistry:
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is utilized in medicinal chemistry as a valuable tool for the design and synthesis of novel drug candidates, potentially leading to the discovery of new therapeutic agents with improved efficacy and safety profiles.
Used in Drug Discovery Efforts:
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is employed in drug discovery efforts to explore its potential bioactivity and therapeutic applications, with the aim of identifying new treatment options for various diseases and conditions.
Used in Bioactivity Studies:
In bioactivity studies, 6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is investigated for its potential to interact with biological targets, which could lead to the development of new therapeutic agents with novel mechanisms of action.
Used in Drug Synthesis:
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is used as a key intermediate in the synthesis of pharmaceutical compounds, contributing to the creation of new drugs with potential applications across various medical fields.

Upstream product

• 147610-84-2 6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate 
• 138163-12-9 benzyl 4-methylene-1-piperidinecarboxylate 
• 1419221-95-6 6-benzyl 1-methyl 6-azaspiro[2.5]octane-1,6-dicarboxylate 

Downstream Products

• 147610-86-4 benzyl 1-(tert-butoxycarbonylamino)-6-azaspiro[2.5]octane-6-carboxylate 
• 1088497-66-8 (4-cyclohexylmethyl-piperazin-1-yl)-[6-(tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone 
• 1088497-82-8 (4-cyclohexyl-piperazin-1-yl)-((R)-6-phenethyl-6-aza-spiro[2.5]oct-1-yl)-methanone 
• 1088497-81-7 (4-cyclohexyl-piperazin-1-yl)-((S)-6-phenethyl-6-aza-spiro[2.5]oct-1-yl)-methanone 
• 1088498-31-0 (R)-1-(4-cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088498-29-6 (S)-1-(4-cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088498-30-9 1-(4-cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088498-05-8 (4-cyclobutyl-piperazin-1-yl)-[6-(4-methoxy-phenyl)-6-aza-spiro[2.5]oct-1-yl]-methanone 
• 1088497-68-0 (4-methyl-piperazin-1-yl)-[6-((E)-3-phenyl-allyl)-6-aza-spiro[2.5]oct-1-yl]-methanone 
• 1088498-32-1 1-(piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088497-69-1 (4-methyl-1-piperazin-1-yl)-(6-phenethyl-6-aza-spiro[2.5]oct-1-yl)-methanone 

Relevant articles and documents

ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES

The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition

A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only σ2 (62% at 10 μM). Compound 6s demonstrated free-plasma exposures above the IC50 (～50×) with a brain-to-plasma ratio of ～3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

N-PIPERIDIN-4-YL DERIVATIVES

The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.

SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES

Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith